Share count has only gone from 8.3M-8.5M since 2022. Not much warrant activity to work through either. Very surprised to see dilution has been minimal here. One would think this would get a pop soon...
Earnings supposedly on 5/15/23. Wondering how that $11.8M cash on hand is holding up.
Does seem like it could be building up to something. I guess time will tell.
Picked up a bunch of shares under $2.50 earlier. This company has POTENTIAL!
BIAF: Hey, King EZ, I had to WAIT until it settled-down, but jumped-on some. Their (Medical) news today looks damn important for perhaps a long-term run here. GOOD LUCK!!
$BIAF: Beat me by a minute........ WOooooooooooohhoooooooooooo
Ohhhhhhhh yaaaaaaaaaaaaaa............. I see it
Can it stay over $2
Nice news .. Noninvasive Test Developed Using Machine Learning Detects Early-Stage Lung Cancer with High Sensitivity and Specificity
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced publication of “Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning” detailing results of the Company’s clinical trial for its non-invasive diagnostic CyPath® Lung in Respiratory Research, one of the leading peer-reviewed open access journals in the field of respiratory medicine.
CyPath® Lung showed 92% sensitivity and 87% specificity in high-risk patients who had nodules smaller than 20 millimeters or no nodules in the lung, with an area under the ROC curve of 94%. Overall, the test resulted in specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer. More than half of those in the cancer cohort had early Stage I or II lung cancer. CyPath® Lung detected multiple forms of cancer including adenocarcinoma, squamous cell carcinoma and small cell lung cancer.
“The fact that CyPath® Lung can accurately predict lung cancer at an early stage in patients with small nodules is particularly important. Findings of lesions between six and 20 millimeters as a result of lung cancer screening can lead to unnecessary invasive procedures or a ‘watchful waiting’ period for patients,” said Vivienne Rebel, MD, PhD, bioAffinity Chief Medical and Science Officer and Executive Vice President. “Our test is intended for use with patients who display these indeterminant nodules to increase the accuracy of lung cancer screening and provide certainty for patients and their physicians.”
“CyPath® Lung uses an automated flow-based approach combined with machine learning that can be put into routine lab use without requiring expert evaluation of samples or being subject to operator bias,” said Madeleine Lemieux, PhD, who is first author and led development of the automated analysis used in CyPath® Lung. “The entire sample is rapidly analyzed which ensures maximal sensitivity. The automated, numerical analysis captures complex interactions between lung cancer and the micro-environment to reliably predict the presence of lung cancer that would not be possible for even expert individuals to do from visual flow data.”
Before working with bioAffinity Technologies, Dr. Lemieux was a computational biologist at the Dana Farber Institute and Harvard Medical School. She has contributed to more than 40 publications leveraging data from high-throughput platforms. Dr. Lemieux and Dr. Rebel began their successful collaboration during their doctoral studies.
CyPath® Lung uses flow cytometry, a method able to interrogate individual cells in a fraction of a second, and automated analysis to identify parameters in sputum that are indicative of cancer. Unlike genomic or other molecular markers used in liquid biopsies, bioAffinity’s CyPath® technology does not collect genetic material for evaluation. Instead, CyPath® Lung analyzes the lung micro-environment and identifies whole cell populations that indicate cancer is present in the lung.
Insiders here have lost their honey pot... the complete lack of movement has wreaked havoc on their cost to borrow income.
I see a pop coming here soon. They will once again loan out all their shares on said pop and collect interest.
Then most likely they will take that interest and buyback at much lower prices, once they have driven the price down to new lows.
Correct me if I'm wrong but I see nothing in any prospectus keeping pre-ipo shareholders from selling SOME of their non-restricted securities. Also some of their restricted holdings will soon be vested and able to be exercised.
Per the investment prospectus, not all of the 6 million previously issued shares are restricted. Some of the stock options are "currently exercisable or exercisable within 60 days"
the last IPO Prospectus after certification states:
Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. In computing the number of shares beneficially owned by a person or entity and the percentage ownership of that person or entity in the table below, all shares subject to options and warrants were deemed outstanding if such securities are currently exercisable, or would vest based on service-based vesting conditions within 60 days of August 17, 2022. These shares were not deemed outstanding, however, for the purpose of computing the percentage ownership of any other person or entity.
I mean I could be reading this wrong, but this would lead to me to expect to see more public market dilution adding to the float around October 16th-17th??? The number of OS shown by brokers is already incorrect.
From what I am reading I believe Dilution Tracker to be correct and the OS is now around 8.38 million shares, with insiders owning probably somewhere around 3 million of it.
I was not referring to the underwriters. Shorts are usually dealt with on a broker to broker and transfer agent basis. The underwriters just drive price action, exercise, and sell shares into the market. That is until their lockup period is up and then they are basically a shareholder like the rest of us, unless there is more issuance. I was mainly referring to the decrease in share availability not being reflected in the short interest. I did not screen shot shares available last week so I do no remember the exact number, but it was not 0.
Underwriter's can't lend out shares to short for 30 days after the IPO launch. This was an early Sept. baby.
Does your broker show shares available to borrow?
I am seeing zero share available but only a 0.62% short interest on my broker.
Fintel also showing zero shares available but only 0.20% short interest.
Im no genius but this doesn't add up...
They also just dropped the share price below the bid several times today, without filling a single share. So when does the order book/lvl 2 actually start to matter?
It can always go down. Insider ownership here gettin rich off loaning out shares for interest. With the way this trades I wouldn't doubt there's more shares owned than are actually in the float. The volume here just doesn't make sense. They will be able to continue to paint the books until all warrants are exercised and there's no ability to fudge the numbers anymore. That may never happen...
I agree that the news was pretty much moot. I bet it was just a fake pump to create some volume for short covering. Now, they will re-short it all over again... And sell exercised shares into the market to manipulate and create the down trend they want.
Like I keep saying.. Its trash underwriters... Go look at their history, they kill 90% of the companies they IPO. Their greed is beyond immense and the SEC won't shut it down just like they won't shut down PFOF. They don't care about a free market. They only care about a controllable market. There is no intention of protecting shareholders' interests.
The only way to make $$$$ in a shit market. Let them pump! :)
Complete fluff! All this tells us is what we already knew when the IPO happened. Just a rehash of old news!
wow, they bought higher than trading price. This says something big is coming.
News: BioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities.
Investors participating in bioAffinity Technologies’ financing exercised a total of 725,576 tradeable warrants at a price of $7.35 per share and 310,910 non-tradable warrants at a price of $7.656 per share. Combined with the Company's underwritten public offering of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant and one non-tradeable warrant, in which the Company announced the receipt of gross proceeds of approximately $7.9 million, the Company has received an aggregate of approximately $15.6 million as of September 28, 2022.
The Company intends to use the proceeds from the offering to expand existing operations and the commercialization of CyPath® Lung, a noninvasive test for the early detection of lung cancer which uses flow cytometry to count and characterize cells in a person’s sputum, or phlegm. The test’s automated analysis of the flow cytometry data detects cell populations that indicate cancer is present. CyPath® Lung has the potential to increase overall diagnostic accuracy of lung cancer diagnosis leading to increased survival while lowering the number of unnecessary invasive procedures, reducing patient anxiety, and lowering medical costs.
Proceeds may also be used in the Company’s pursuit of regulatory approvals and research and development of additional diagnostics, cancer therapeutics, and for working capital and general corporate purposes.
Total shares for BIAF as shown in prospectus 424B4 filed on 9/2/22:
6,098,203 Existing shareholders prior to IPO
1,282,600 New shares sold with IPO
7,380,803 Total as of June 30, 2022
Issuance Details: (there is a difference of 270,629 more than what's stated above)
2,570,650 shares of Common Stock issuable upon the exercise of the Warrants underlying the Units sold in this Offering;
192,390 shares of Common Stock issuable upon the exercise of the Over-Allotment Option
192,390 shares of Common Stock issuable upon the exercise of 192,390 Tradeable Warrants issuable upon the exercise of the Over-Allotment Option
192,390 shares of Common Stock issuable upon the exercise of 192,390 Non-tradeable Warrants issuable upon the exercise of the Over-Allotment Option
25,562 shares of Common Stock issuable upon the exercise of the Representative’s Warrant and 29,464 shares of Common Stock issuable upon the exercise of the Placement Agent’s Warrant
756,558 shares of Common stock issuable upon the conversion of Series A Preferred ?Stock
871,240 shares of ?Common Stock issuable on the exercise of stock options; and
2,850,252 shares of Common Stock issuable on the exercise of outstanding warrants issued to the holders of our convertible notes with a weighted average exercise price equal to $5.25 per share.
Warrants are exercisable at $7.35
Do you know what the exercise price is for the warrants and when can they be exercised
BIAFW warrants up +50% maybe commons will follow
I don't believe that to be half the float...
I understand that 1.3mill should be the float according to the information provided by our brokers. But when I dug through the filings earlier this week I came up with around 3 mil...
Dilution tracker shows OS to be around 7.3 mill. I don't pay their subscription right now, so I don't know exactly how much of the 7.3 mill is actually issued, but the company did do some sort of split before they IPO'd. I am wondering if there are previously issued shares now being sold into the market.
I am drinking right now due to the ETH merge, and I have to take off close to a megawatt of hash-power off blockchains, but I will deep dive as much as possible into the actual share structure and report back once I am sober...
Even still, share structure doesn't seem to matter these days. Institutions seem to have limitless ability to issue endless shares to create the movement they want. all because of inflation. This ability to sell endless amounts of shares regardless of SS has been quite prevalent since the GME debacle.
What happen after 30 days
610k in short exempts today!! That is half the float
This is a 9-day-old IPO, usually, there is a lock-up period. outstanding shares is only 2,700,000. Only 1,000,000 shares they could sell if no lock-up period.
The company could have been selling shares into the news
It's the dumbecrats they want all our money ??
Trash greedy underwriters...
These underwriters kill every stock that choses to IPO with them.
They really suck at what they do... Need to learn how to sell shares into the market.. But then again I guess that would actually require them to work for their money...